[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"greater-occipital-nerve-block\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:greater-occipital-nerve-block":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,74,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100636654","greater-occipital-nerve-block-for-migraine-with-medication-overuse-headache-100636654",false,"NCT07568496","Greater Occipital Nerve Block for Migraine With Medication Overuse Headache","GONB_MOH","Inclusion Criteria:\n\n* Patients who have a diagnosis of migraine with medication overuse headache according to ICHD-3 criteria confirmed by a neurologist\n* Female patients will be screened for pregnancy planning and married female patients must undergo a urine pregnancy test\n\nExclusion Criteria:\n\n* Patients who have other types of headache disorders other than migraine\n* Patients who have a previous history of allergy to corticosteroid or lidocaine\n* Patients who had previous skull surgery\n* Pregnant women\n* Patients with a history of uncontrolled depression, or psychosis\n* Patients who get or plan to get CGRP-targeted therapies or botulinum toxin injection\n* Patients with an increased risk of bleeding or underlying bleeding disorders","ALL","18 Years","80 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","Migraine is among the leading causes of disability worldwide. Inappropriate use of acute medications in the setting of primary headache, particularly migraine can result in a debilitating condition known as medication overuse headache (MOH). Treatment of MOH is challenging and the primary therapeutic approach is reducing painkillers which helps decrease the number of headache days. As a part of the detoxification process to discontinue acute medications, bridging therapy is often needed to reduce withdrawal headache. Currently, there are data supporting the use of greater occipital nerve block as a preventive treatment in chronic migraine, but no placebo-controlled trial has evaluated the efficacy of greater occipital nerve block in MOH. Therefore, this research aims to demonstrate the efficacy of greater occipital nerve block in detoxification of migraine patients with MOH. Patients will be recruited from Headache Clinic at 3 centers in Thailand from February 2026 to January 2028. After recruitment, patients will be randomized into 2 groups at a 1:1 ratio using a block of four, namely group A and B. A 5-mL syringe of 2 mL of lidocaine 2% and 2 mL of methylprednisolone 40 mg\u002FmL (80 mg) will be prepared for each patient in group while a 5-mL syringe of 4 mL normal saline will be prepared for each patient in group B. Monthly headache days, duration, severity, acute medication type and number of usage days and relative headache status according to a 5-point Likert scale will be investigated at the 2 weeks, 1st, 2nd and 3rd month, MIDAS at the end of 3rd month.",[27,28,29],"Migraine Disorders","Medication Overuse Headache","Greater Occipital Nerve Block",[31,32,33,34,35,36],"GONB","Nerve Block","Detoxification","MOH","Methylprednisolone","Lidocaine","NOT_YET_RECRUITING","2026-05-11",{"date":40,"type":41},"2026-05-13","ACTUAL",{"date":43,"type":21},"2026-05-01",{"date":45,"type":21},"2028-11-01",{"name":47,"class":48},"Mahidol University","OTHER",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100634133","botulinum-toxin-andor-greater-occipital-nerve-block-for-patients-with-chronic-migraine-100634133","NCT07535723","Botulinum Toxin and\u002For Greater Occipital Nerve Block for Patients With Chronic Migraine","Inclusion Criteria:\n\n* Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3): headache occurring on ≥15 days per month for more than three months, with at least 8 days per month exhibiting migraine features. (International Headache Society, 2013)\n* Age \\> 18 years\n* Stable preventive migraine regimen for at least two months prior to recruitment\n\nExclusion Criteria:\n\n* Co-morbid other\n* Prior treatment with BoNT-A or GONB for headache within the previous 3 months.\n* Known hypersensitivity to BoNT-A or local anesthetics.\n* Cervical anatomical abnormalities that hinder proper localization of injection sites or compromise the safety of the procedure\n* Neuromuscular junction disorders (e.g., myasthenia gravis).\n* Coagulation disorders or anticoagulant therapy that contraindicates nerve block.\n* Significant psychiatric comorbidity that would impair proper pre and post treatment assessment.\n* Pregnancy.",{"count":57,"type":21},90,[24],"Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.",[61,62,29,63],"Chronic Migraine Headache","OnabotulinumtoxinA","Combination Therapy","2026-04-15",{"date":66,"type":41},"2026-04-17",{"date":68,"type":21},"2026-04",{"date":70,"type":21},"2026-12",{"name":72,"class":48},"Beni-Suef University",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":73},"100630436","treatment-response-in-patients-with-medication-overuse-headache-100630436","NCT07487649","Treatment Response in Patients With Medication-Overuse Headache","Factors Affecting Treatment Response in Patients With Medication-Overuse Headache Undergoing Greater Occipital Nerve Blockade","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of medication-overuse headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)\n* Diagnosis of medication-overuse headache associated with the use of triptans or nonsteroidal anti-inflammatory drugs\n* Previous diagnosis of chronic migraine or chronic tension-type headache according to the ICHD-3 criteria\n\nExclusion Criteria:\n\n* History of severe head or neck trauma or previous neurosurgical intervention\n* Presence of a severe psychiatric disorder (e.g., severe depression, schizophrenia)\n* History of infectious disease, chronic inflammatory disease, or malignancy\n* Previous diagnosis of secondary headache\n* History of substance abuse\n* Pregnancy or breastfeeding\n* History of an additional neurological disorder (e.g., cerebrovascular disease, multiple sclerosis)\n* Difficulty with cooperation\n* Presence of a concomitant systemic disease that may affect quality of life (e.g., congestive heart failure, chronic kidney disease, chronic liver disease, pulmonary disease, uncontrolled diabetes, or peripheral vascular disease)","65 Years",{"count":83,"type":21},70,"OBSERVATIONAL","The aim of this study to evaluate pre-injection patient-related factors that may influence treatment response in patients with medication-overuse headache who underwent ultrasound-guided greater occipital nerve block.",[87,88,89,29],"Medication-overuse Headache","Treatment","Headache","RECRUITING","2026-03-17",{"date":93,"type":41},"2026-03-23",{"date":91,"type":41},{"date":96,"type":21},"2026-05-30",{"name":98,"class":99},"Sultan 1. Murat State Hospital","OTHER_GOV",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":73},"100619626","clinical-study-of-myofascial-trigger-pointsmtrps-injection-in-the-treatment-of-chronic-migraine-100619626","NCT07347067","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Musculoskeletal Pain(CMP), Chronic Migraine and Cervicogenic Headache","Inclusion Criteria:\n\n* Diagnosed with migraine by at least two pain specialists or neurologists;\n* Disease duration of at least 3 months;\n* Age between 18 and 65 years;\n* Numerical Rating Scale (NRS) score ≥ 3 despite conservative pharmacological treatment;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of allergy to trial medications such as corticosteroids;\n* Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;\n* Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;\n* Inability to use pain assessment scales;\n* Presence of local or systemic infection;\n* Pregnant or lactating patients.",{"count":108,"type":21},1036,[24],"Chronic migraine is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with chronic migraine. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and greater occipital nerve block injection in treating chronic migraine. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or greater occipital nerve. After treatment, patients will be followed up for 2 years. Their NRS scores, attack frequency, attack duration, HIT-6 scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for chronic migraine is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.",[112,61,29],"Myofascial Trigger Points","2026-01-11",{"date":115,"type":41},"2026-01-16",{"date":117,"type":41},"2025-12-01",{"date":119,"type":21},"2027-06-01",{"name":121,"class":48},"Beijing Tiantan Hospital"]